West Pharmaceutical (NYSE: WST) CFO awarded new RSUs and stock options

Q: How many restricted stock units were granted to the WST CFO?

Robert W. McMahon was granted 3,082 restricted stock units . Each unit represents a contingent right to receive one share of West Pharmaceutical Services common stock, subject to vesting conditions over four years starting March 1, 2027.

Q: What stock options did the WST CFO receive in this Form 4 filing?

The CFO received a grant of 7,337 stock options , described as a right to buy West Pharmaceutical Services common stock. These options vest in four equal annual installments beginning March 1, 2027, encouraging longer‑term retention and performance.

Q: When do the WST CFO’s restricted stock units begin vesting?

The restricted stock units begin vesting on March 1, 2027 . Vesting occurs in four equal annual installments from that date, so full vesting spans four years, assuming continued employment and satisfaction of any applicable conditions.

Q: When do the WST CFO’s stock options start to vest?

The stock options start vesting on March 1, 2027 . Similar to the restricted stock units, they vest in four equal annual installments, spreading the potential ownership benefit for the CFO over a four‑year period tied to ongoing service.

Q: Does this WST Form 4 show insider buying or selling on the market?

This Form 4 reflects grant or award acquisitions , not open‑market buying or selling. The CFO received restricted stock units and stock options as part of compensation, with vesting scheduled over several years rather than immediate market transactions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

McMahon Robert W. reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services granted its SVP & Chief Financial Officer, Robert W. McMahon, two equity awards. He received 3,082 restricted stock units, each representing the right to one share of common stock, and options for 7,337 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider McMahon Robert W.

Role SVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Rst. Stock Unit	3,082	$0.00	--
Grant/Award	Stock Option (Right to Buy)	7,337	$0.00	--

Holdings After Transaction: Rst. Stock Unit — 3,082 shares (Direct); Stock Option (Right to Buy) — 7,337 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of WST common stock. The restricted stock units vest in four equal annual installments beginning on March 1, 2027. The stock option vests in four equal annual installments beginning on March 1, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 11:26 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMahon Robert W.

(Last)

(First)

(Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON

19341

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Rst. Stock Unit	⁽¹⁾	03/01/2026		A		3,082		⁽²⁾	⁽²⁾	Common Stock	3,082	$0	3,082	D
Stock Option (Right to Buy)	$254.34	03/01/2026		A		7,337		⁽³⁾	03/01/2036	Common Stock	7,337	$0	7,337	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.

3. The stock option vests in four equal annual installments beginning on March 1, 2027.

	/s/ Caitlin Hippeli, as an agent for Robert W. McMahon	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did WST report for Robert W. McMahon?

West Pharmaceutical Services reported that Robert W. McMahon received equity awards, including restricted stock units and stock options. These awards form part of his compensation and align his interests with shareholders over a multi‑year vesting period tied to continued service.

How many restricted stock units were granted to the WST CFO?

Robert W. McMahon was granted 3,082 restricted stock units. Each unit represents a contingent right to receive one share of West Pharmaceutical Services common stock, subject to vesting conditions over four years starting March 1, 2027.

What stock options did the WST CFO receive in this Form 4 filing?

The CFO received a grant of 7,337 stock options, described as a right to buy West Pharmaceutical Services common stock. These options vest in four equal annual installments beginning March 1, 2027, encouraging longer‑term retention and performance.

When do the WST CFO’s restricted stock units begin vesting?

The restricted stock units begin vesting on March 1, 2027. Vesting occurs in four equal annual installments from that date, so full vesting spans four years, assuming continued employment and satisfaction of any applicable conditions.

When do the WST CFO’s stock options start to vest?

The stock options start vesting on March 1, 2027. Similar to the restricted stock units, they vest in four equal annual installments, spreading the potential ownership benefit for the CFO over a four‑year period tied to ongoing service.

Does this WST Form 4 show insider buying or selling on the market?

This Form 4 reflects grant or award acquisitions, not open‑market buying or selling. The CFO received restricted stock units and stock options as part of compensation, with vesting scheduled over several years rather than immediate market transactions.